Samsung Bioepis Presented Results of SB12 (biosimilar, eculizumab) for the treatment of Paroxysmal Nocturnal Hemoglobinuria at EHA 2023
Shots:
- The company highlighted the results from the population PK/PD/efficacy modeling evaluating SB12 vs eculizumab in patients with PNH
- The modeling analysis showed similarities of PK, PD, and efficacy profiles b/w SB12 and reference eculizumab in the pooled population of healthy volunteers and patients with PNH thus supporting the totality of evidence on biosimilarity for SB12
- SB12 received marketing authorization from the EC on May 2023 under the brand name Epysqli, as a biosimilar to Soliris for the treatment of adult and children’s patients with PNH
Ref: Samsung Bioepis | Image: Samsung Bioepis
Related News:- Samsung Bioepis Receives EC’s Marketing Authorization for Epysqli (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
